Prof. Eran Leitersdorf is a graduate of the Hebrew University-Hadassah Medical School in Jerusalem. He trained in Internal Medicine, Lipid Metabolism and Molecular Genetics at the Hadassah Hebrew University Medical Center, at the laboratory of the Nobel laureates MS Brown and JL Goldstein of the Southwestern Medical Center in Dallas, the laboratory of Drs. A. Motulsky of the George Washington University in Seattle, and at the laboratory of Dr. J.-C. Fruchart of the Pasteur Institute in Lille, France. He is the recipient of numerous awards including five Hebrew University – Faculty of Medicine Prizes, the Fogarty (NIH) International Research Fellowship and the International Atherosclerosis (IAS) Award. His main research interests are in Lipid Metabolism, Atherosclerosis, Molecular Genetics and Drugs Affecting Lipid Metabolism. He has published over 180 original papers, reviews, editorials and commentaries and is a full Professor at the Hebrew University. He was the founder and first Chairman of the Israeli Atherosclerosis Society and a member of the European and the International Atherosclerosis Societies. He was an Associate Editor of the journals “Atherosclerosis” and “Arteriosclerosis, Thrombosis and Vascular Biology” and is a reviewer for other scientific journals and National scientific organizations. His clinical interests are focused on the prevention of atherosclerosis through lipid modification. He is heading the Center for Research, prevention and Treatment of Atherosclerosis at Hadassah, and previously chaired one of Hadassah’s departments of medicine and in 2002 led the development of Hadassah’s first Electronic Medical Records (EMR) system. In 2009 he was elected Dean of the Hebrew University Faculty of Medicine, which includes the School of Medicine, The School of Nursing, The School of Public Health, The School of Pharmacy and The School of Occupational Therapy. After completing his four years term as a Dean, Prof. Leitersdorf spent two years at Stanford as a Visiting professor in Medical Informatics of Stanford Healthcare and in 2015 returned to the Hadassah as the Chairman of the Center for Research, Prevention and Treatment of Atherosclerosis and The Hadassah’s Helsinki Committee (Institutional Review Board).